Autism Treatment Network Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2012
NCT01745497
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

clonidine (catapres) (1 trial)

ferrous sulfate (1 trial)

Drugs in Phase 1 Trials (2)

maltose (1 trial)

visibiome (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Child Development Disorders, Pervasive (Phase 2)

Disease (Phase 2)

Parasomnias (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Sleep Wake Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4